Observational Study of Neurofilament Light Chain (NfL) Levels in Asymptomatic Carriers of the TTR Gene Variants and Patients With hATTR Amyloidosis With Polyneuropathy, Including Patients Who Undergo Treatment Change - NeuroFeeL Study.
In: Clinical Trials Week, 2024-04-30, S. 1340-1340
serialPeriodical
Zugriff:
This article discusses a newly launched clinical trial, NCT06360289, which aims to evaluate the potential value of Neurofilament Light Chain (NfL) as a biomarker for diagnosis, disease onset detection, disease progression monitoring, and treatment response in asymptomatic carriers of TTR variants and symptomatic hATTR amyloidosis patients with polyneuropathy. The trial will involve extracting participants' data from medical records and collecting blood samples for analysis. The study is observational in nature and will follow a cohort design. The estimated enrollment for the study is 500 participants, and the estimated completion date is April 2027. The study is being conducted by Alnylam Pharmaceuticals and is not yet recruiting participants. [Extracted from the article]
Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Observational Study of Neurofilament Light Chain (NfL) Levels in Asymptomatic Carriers of the TTR Gene Variants and Patients With hATTR Amyloidosis With Polyneuropathy, Including Patients Who Undergo Treatment Change - NeuroFeeL Study.
|
---|---|
Zeitschrift: | Clinical Trials Week, 2024-04-30, S. 1340-1340 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6772 (print) |
Schlagwort: |
|
Sonstiges: |
|